Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Kuros Bioscience Ltd
(OP:
CSBTF
)
25.53
UNCHANGED
Last Price
Updated: 11:21 AM EST, Nov 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Kuros Bioscience Ltd
Kuros Biosciences Expands into Extremities Markets
November 19, 2024
Via
ACCESSWIRE
Kuros Reports 149% Increase in Direct MagnetOs Sales and Exceeds Cash Flow Breakeven in the First Nine Months of 2024
October 09, 2024
Via
ACCESSWIRE
Kuros Biosciences Reports First Half of 2024 Results
August 08, 2024
Via
ACCESSWIRE
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft
June 25, 2024
Via
ACCESSWIRE
Kuros Reports Corporate Highlights as of Q1 2024 Including Increase in Direct MagnetOsTM Sales
April 23, 2024
Via
ACCESSWIRE
Annual General Meeting of Kuros Biosciences Approves All Resolutions
April 17, 2024
Via
ACCESSWIRE
Kuros Reports 163% Growth in Direct MagnetOs Sales and 153% Increase in Total Medical Device Sales for the Full Year 2023
March 12, 2024
Via
ACCESSWIRE
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update
March 07, 2024
Via
ACCESSWIRE
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
January 31, 2024
Via
ACCESSWIRE
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
January 30, 2024
Via
ACCESSWIRE
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA
January 03, 2024
Via
ACCESSWIRE
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
December 26, 2023
Via
ACCESSWIRE
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
November 28, 2023
Via
ACCESSWIRE
Kuros Reports a 150% Increase in Direct MagnetOs Sales in the First Nine Months of 2023 and Announces Changes Within the Executive Management
October 12, 2023
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.